advertisement

Topcon

Cirafici P 12

Showing records 1 to 12 | Display all abstracts from Cirafici P

90566 Point-wise correlations between 10-2 Humphrey visual field and OCT data in open angle glaucoma
Cirafici P
Eye 2021; 35: 868-876
90166 Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial
Rossetti L
Journal of Glaucoma 2020; 29: 513-520
90566 Point-wise correlations between 10-2 Humphrey visual field and OCT data in open angle glaucoma
Cirafici P
Eye 2021; 35: 868-876
90166 Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial
Iester M
Journal of Glaucoma 2020; 29: 513-520
90566 Point-wise correlations between 10-2 Humphrey visual field and OCT data in open angle glaucoma
Maiello G
Eye 2021; 35: 868-876
90166 Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial
Tranchina L
Journal of Glaucoma 2020; 29: 513-520
90566 Point-wise correlations between 10-2 Humphrey visual field and OCT data in open angle glaucoma
Ancona C
Eye 2021; 35: 868-876
90166 Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial
Ottobelli L
Journal of Glaucoma 2020; 29: 513-520
90566 Point-wise correlations between 10-2 Humphrey visual field and OCT data in open angle glaucoma
Masala A; Traverso CE
Eye 2021; 35: 868-876
90166 Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial
Coco G; Calcatelli E
Journal of Glaucoma 2020; 29: 513-520
90566 Point-wise correlations between 10-2 Humphrey visual field and OCT data in open angle glaucoma
Iester M
Eye 2021; 35: 868-876
90166 Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial
Ancona C; Cirafici P; Cirafici P; Manni G
Journal of Glaucoma 2020; 29: 513-520

Issue 21-3

Change Issue


advertisement

Oculus